Login to Your Account

Clinic Roundup

Friday, August 16, 2013
• Opko Health Inc., of Miami, surpassed 50 percent enrollment in the second Phase III trial of Rayaldy, an oral vitamin D pro-hormone treatment for patients with secondary hyperparathyroidism, Stage III or IV chronic kidney disease and vitamin D insufficiency. Identical to the initial Phase III, the randomized, double-blind, placebo-controlled, multisite study is designed to establish the safety and efficacy of Rayaldy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription